左氧氟沙星FDA说明书

左氧氟沙星FDA说明书
左氧氟沙星FDA说明书

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LEVAQUIN? safely and effectively. See full prescribing information

for LEVAQUIN ? .

LEVAQUIN? (levofloxacin) Tablet, Film Coated for Oral use LEVAQUIN? (levofloxacin) Solution for Oral use

LEVAQUIN? (levofloxacin) Injection, Solution, Concentrate for Intravenous use

LEVAQUIN? (levofloxacin) Injection, Solution for Intravenous use

Initial U.S. Approval: 1996

WARNING:

See full prescribing information for complete boxed warning. Fluoroquinolones, including LEVAQUIN?, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants [See Warnings and Precautions (5.1)]. Fluoroquinolones, including LEVAQUIN?, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid LEVAQUIN? in patients with a known history of myasthenia gravis [See Warnings and Precautions (5.2)].

effectiveness of LEVAQUIN? and other antibacterial drugs, LEVAQUIN? should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

—————————RECENT MAJOR CHANGES——————— Warnings and Precautions

? Peripheral Neuropathy (5.8) 07/2013 —————————INDICATIONS AND USAGE———————— LEVAQUIN? is a fluoroquinolone antibacterial indicated in ad ults (≥18 years of age) with infections caused by designated, susceptible bacteria (1, 12.4).

? Pneumonia: nosocomial (1.1) and community acquired (1.2, 1.3)

? Acute bacterial sinusitis (1.4)

? Acute bacterial exacerbation of chronic bronchitis (1.5)

? Skin and skin structure infections: complicated (1.6) and uncomplicated (1.7)

? Chronic bacterial prostatitis (1.8)

? Urinary tract infections: complicated (1.9, 1.10) and uncomplicated

(1.12)

? Acute pyelonephritis (1.11)

? Inhalational anthrax, post-exposure (1.13)

? Plague (1.14)

———————DOSAGE AND ADMINISTRATION——————— ? Dosage in patients with normal renal function (2.1)

Type of Infection Dose Every 24

hours Duration (days)

Nosocomial Pneumonia (1.1) 750 mg 7–14 Community Acquired Pneumonia (1.2) 500 mg 7–14 Community Acquired Pneumonia (1.3) 750 mg 5 Acute Bacterial Sinusitis (1.4) 750 mg 5

500 mg 10–14 Acute Bacterial Exacerbation of Chronic

Bronchitis (1.5)

500 mg 7 Complicated Skin and Skin Structure Infections

(SSSI) (1.6)

750 mg 7–14 Uncomplicated SSSI (1.7) 500 mg 7–10 Chronic Bacterial Prostatitis (1.8) 500 mg 28 Complicated Urinary Tract Infection (1.9) or

Acute Pyelonephritis (1.11)

750 mg 5 Complicated Urinary Tract Infection (1.10) or

Acute Pyelonephritis (1.11)

250 mg 10 Uncomplicated Urinary Tract Infection (1.12) 250 mg 3

Type of Infection Dose Every 24

hours

Duration

(days) Inhalational Anthrax (Post-Exposure) (1.13)

Adults and Pediatric Patients > 50 kg

Pediatric Patients < 50 kg and ≥ 6 months of

age

500 mg

8 mg/kg BID

(not to exceed

250 mg/dose)

60

60 Plague (1.14)

Adults and Pediatric Patients > 50 kg

Pediatric Patients < 50 kg and ≥ 6 months of

age

500 mg

8 mg/kg BID

(not to exceed

250 mg/dose)

10 to 14

10 to 14

? Adjust dose for creatinine clearance < 50 mL/min (2.3, 8.6, 12.3)

? IV Injection, Single-Use or Premix: Slow IV infusion only, over

60 or 90 minutes depending on dose. Avoid rapid or bolus IV (2.5) ? Dilute single-use vials to 5 mg/mL prior to IV infusion (2.6)

? Do not mix with other medications in vial or IV line (2.6) ———————DOSAGE FORMS AND STRENGTHS——————

Formulation (3) Strength

Tablets 250 mg, 500 mg, and 750 mg Oral Solution 25 mg/mL

Injection: single-use vials for dilution 500 mg in 20 mL

750 mg in 30 mL Injection: premix single-use flexible

containers

250 mg in 50 mL

500 mg in 100 mL

750 mg in 150 mL ——————————CONTRAINDICATIONS————————— Known hypersensitivity to LEVAQUIN? or other quinolones (4, 5.3) ———————WARNINGS AND PRECAUTIONS——————— ? Risk of tendinitis and tendon rupture is increased. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroids, and in patients with kidney, heart or lung transplants. Discontinue if pain or inflammation in a tendon occurs

(5.1, 8.5)

? May exacerbate muscle weakness in persons with myasthenia gravis.

Avoid use in patients with a known history of myasthenia gravis (5.2) ? Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose (4, 5.3)

? Hematologic (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses (5.4)

? Hepatotoxicity: Severe, and sometimes fatal, hepatoxicity has been reported. Discontinue immediately if signs and symptoms of hepatitis occur (5.5)

? Central nervous system effects, including convulsions, anxiety, confusion, depression, and insomnia may occur after the first dose. Use with caution in patients with known or suspected disorders that may predispose them to seizures or lower the seizure threshold. Increased intracranial pressure (pseudotumor cerebri) has been reported (5.6)

? Clostridium difficile-associated colitis: evaluate if diarrhea occurs (5.7) ? Peripheral neuropathy: discontinue immediately if symptoms occur in order to prevent irreversibility (5.8)

? Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval (5.9, 8.5)

——————————ADVERSE REACTIONS————————— The most common reactions (≥3%) were nausea, headache, diarrhea, insomnia, constipation and dizziness (6.2).

To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or https://www.360docs.net/doc/9213394164.html,/medwatch.

——————————DRUG INTERACTIONS—————————

Interacting Drug Interaction

Multivalent cation-containing products including antacids, metal cations or didanosine Absorption of levofloxacin is decreased when the tablet or oral solution formulation is taken within 2 hours of these products. Do not co-administer the intravenous formulation in the same IV line with a multivalent cation, e.g., magnesium (2.4, 7.1)

Warfarin Effect may be enhanced. Monitor prothrombin

time, INR, watch for bleeding (7.2)

Antidiabetic agents Carefully monitor blood glucose (5.11, 7.3) ———————USE IN SPECIFIC POPULATIONS——————— ? Geriatrics: Severe hepatotoxicity has been reported. The majority of reports describe patients 65 years of age or older (5.5, 8.5, 17). May

have increased risk of tendinopathy (including rupture), especially

with concomitant corticosteroid use (5.1, 8.5, 17). May be more

susceptible to prolongation of the QT interval. (5.9, 8.5, 17).

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING:

1 INDICATIONS AND USAGE

1.1 Nosocomial Pneumonia

1.2 Community-Acquired Pneumonia: 7–14 day

Treatment Regimen

1.3 Community-Acquired Pneumonia: 5-day

Treatment Regimen

1.4 Acute Bacterial Sinusitis: 5-day and 10–14 day

Treatment Regimens

1.5 Acute Bacterial Exacerbation of Chronic

Bronchitis

1.6 Complicated Skin and Skin Structure Infections

1.7 Uncomplicated Skin and Skin Structure

Infections

1.8 Chronic Bacterial Prostatitis

1.9 Complicated Urinary Tract Infections: 5-day

Treatment Regimen

1.10 Complicated Urinary Tract Infections: 10-day

Treatment Regimen

1.11 Acute Pyelonephritis: 5 or 10-day Treatment

Regimen

1.12 Uncomplicated Urinary Tract Infections

1.13 Inhalational Anthrax (Post-Exposure)

1.14 Plague

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adult Patients with Normal Renal

Function

2.2 Dosage in Pediatric Patients

2.3 Dosage Adjustment in Adults with Renal

Impairment

2.4 Drug Interaction With Chelation Agents:

Antacids, Sucralfate, Metal Cations,

Multivitamins

2.5 Administration Instructions

2.6 Preparation of Intravenous Product

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Tendinopathy and Tendon Rupture

5.2 Exacerbation of Myasthenia Gravis

5.3 Hypersensitivity Reactions

5.4 Other Serious and Sometimes Fatal Reactions

5.5 Hepatotoxicity

5.6 Central Nervous System Effects

5.7 Clostridium difficile-Associated Diarrhea

5.8 Peripheral Neuropathy

5.9 Prolongation of the QT Interval

5.10 Musculoskeletal Disorders in Pediatric Patients

and Arthropathic Effects in Animals

5.11 Blood Glucose Disturbances

5.12 Photosensitivity/Phototoxicity

5.13 Development of Drug Resistant Bacteria

6 ADVERSE REACTIONS

6.1 Serious and Otherwise Important Adverse

Reactions ? Pediatrics: Musculoskeletal disorders (arthralgia, arthritis, tendinopathy, and gait abnormality) seen in more LEVAQUIN?-

treated patients than in comparator. Shown to cause arthropathy and

osteochondrosis in juvenile animals (5.10, 8.4, 13.2). Safety in pediatric patients treated for more than 14 days has not been studied.

Risk-benefit appropriate only for the treatment of inhalational anthrax

(post-exposure) (1.13, 2.2, 8.4, 14.9) and plague (1.14, .2.2, 8.4,

14.10)

See 17 for PATIENT COUNSELING INFORMATION and the FDA-approved Medication Guide

Revised: 05/2014

6.3 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Chelation Agents: Antacids, Sucralfate, Metal

Cations, Multivitamins

7.2 Warfarin

7.3 Antidiabetic Agents

7.4 Non-Steroidal Anti-Inflammatory Drugs

7.5 Theophylline

7.6 Cyclosporine

7.7 Digoxin

7.8 Probenecid and Cimetidine

7.9 Interactions with Laboratory or Diagnostic

Testing

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

12.4 Microbiology

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of

Fertility

13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

14.1 Nosocomial Pneumonia

14.2 Community-Acquired Pneumonia: 7–14 day

Treatment Regimen

14.3 Community-Acquired Pneumonia: 5-day

Treatment Regimen

14.4 Acute Bacterial Sinusitis: 5-day and 10–14 day

Treatment Regimens

14.5 Complicated Skin and Skin Structure Infections

14.6 Chronic Bacterial Prostatitis

14.7 Complicated Urinary Tract Infections and Acute

Pyelonephritis: 5-day Treatment Regimen

14.8 Complicated Urinary Tract Infections and Acute

Pyelonephritis: 10-day Treatment Regimen

14.9 Inhalational Anthrax (Post-Exposure)

14.10 Plague

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 LEVAQUIN? Tablets

16.2 LEVAQUIN? Oral Solution

16.3 LEVAQUIN? Injection, Single-Use Vials

16.4 LEVAQUIN? Injection Pre-Mixed Solution,

Single-Use in Flexible Container

17 PATIENT COUNSELING INFORMATION

17.1 Antibacterial Resistance

17.2 Administration with Food, Fluids, and

Concomitant Medications

17.3 17.4

Serious and Potentially Serious Adverse

Reactions

Drug Interactions with Insulin, Oral

Hypoglycemic Agents, and Warfarin

17.5

17.6

Plague and Anthrax Studies

FDA-Approved Medication Guide

*Sections or subsections omitted from the full prescribing information are

not listed

FULL PRESCRIBING INFORMATION

WARNING:

Fluoroquinolones, including LEVAQUIN? , are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants [See Warnings and Precautions (5.1)].

Fluoroquinolones, including LEVAQUIN?, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid LEVAQUIN? in patients with a known history of myasthenia gravis [See Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE

To reduce the development of drug-resistant bacteria and maintain the effectiveness of LEVAQUIN? and other antibacterial drugs, LEVAQUIN? should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology

and susceptibility patterns may contribute to the empiric selection of therapy.

LEVAQUIN? Tablets/Injection and Oral Solution are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of

the designated microorganisms in the conditions listed in this section. LEVAQUIN? Injection

is indicated when intravenous administration offers a route of administration advantageous to

the patient (e.g., patient cannot tolerate an oral dosage form).

Culture and susceptibility testing

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with LEVAQUIN? may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.

As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with LEVAQUIN?. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.

1.1 Nosocomial Pneumonia

LEVAQUIN? is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)].

1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen

LEVAQUIN? is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)].

MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.

1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen

LEVAQUIN? is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)].

1.4 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens LEVAQUIN? is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)].

1.5 Acute Bacterial Exacerbation of Chronic Bronchitis

LEVAQUIN? is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.

1.6 Complicated Skin and Skin Structure Infections

LEVAQUIN? is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)].

1.7 Uncomplicated Skin and Skin Structure Infections

LEVAQUIN? is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes.

1.8 Chronic Bacterial Prostatitis

LEVAQUIN? is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)].

1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen

LEVAQUIN? is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)].

1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen LEVAQUIN? is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)].

1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen

LEVAQUIN? is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)].

1.12 Uncomplicated Urinary Tract Infections

LEVAQUIN? is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.

1.13 Inhalational Anthrax (Post-Exposure)

LEVAQUIN? is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of LEVAQUIN? is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. LEVAQUIN? has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of LEVAQUIN? in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged LEVAQUIN? therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)].

1.14 Plague

LEVAQUIN? is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of LEVAQUIN? could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)].

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adult Patients with Normal Renal Function

The usual dose of LEVAQUIN? Tablets or Oral Solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1. The usual dose of LEVAQUIN? Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours, as indicated by infection and described in Table 1.

These recommendations apply to patients with creatinine clearance ≥ 50 mL/min. For patients with creatinine clearance <50 mL/min, adjustments to the dosing regimen are required [see Dosage and Administration (2.3)].

Table 1: Dosag e in Adult Patients with Normal Renal Function (creatinine clearance ≥ 50 mL/min) Type of Infection* Dosed Every 24 hours Duration

(days)? Nosocomial Pneumonia 750 mg 7–14 Community Acquired Pneumonia? 500 mg 7–14 Community Acquired Pneumonia§ 750 mg 5 Acute Bacterial Sinusitis 750 mg 5

500 mg 10–14

Table 1: Dosag e in Adult Patients with Normal Renal Function (creatinine clearance ≥ 50 mL/min) Type of Infection* Dosed Every 24 hours Duration

(days)? Acute Bacterial Exacerbation of Chronic Bronchitis 500 mg 7 Complicated Skin and Skin Structure Infections (SSSI) 750 mg 7–14 Uncomplicated SSSI 500 mg 7–10 Chronic Bacterial Prostatitis 500 mg 28 Complicated Urinary Tract Infection (cUTI) or

Acute Pyelonephritis (AP)?

750 mg 5

Complicated Urinary Tract Infection (cUTI) or

Acute Pyelonephritis (AP)#

250 mg 10 Uncomplicated Urinary Tract Infection 250 mg 3

Inhalational Anthrax (Post-Exposure), adult and pediatric patients > 50 kg T,?

Pediatric patients < 50 kg and ≥ 6 months of age T,?

500 mg

see Table 2 below (2.2)

60?

60?

Plague, adult and pediatric patients > 50 kg à Pediatric patients < 50 kg and ≥ 6 months of age

500 mg

see Table 2 below (2.2)

10 to 14

10 to 14

Due to the designated pathogens [see Indications and Usage (1)].

? Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.

? Due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Indications and Usage (1.2)].

§ Due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Indications and Usage (1.3)].

? This regimen is indicated for cUTI due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and AP due to E. coli, including cases with concurrent bacteremia.

# This regimen is indicated for cUTI due to Enterococcus faecalis, Enterococcus cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa; and for AP due to E. coli.

T Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized B. anthracis. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit [see Clinical Studies (14.9)].

? The safety of LEVAQUIN? in adults for durations of therapy beyond 28 days or in pediatric patients for durations beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see Warnings and Precautions (5.10), Use in Specific Populations (8.4), and Clinical Studies (14.9)]. Prolonged LEVAQUIN? therapy should only be used when the benefit outweighs the risk.

à Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis. Higher doses of LEVAQUIN? typically used for treatment of pneumonia can be used for treatment of plague, if clinically indicated.

2.2 Dosage in Pediatric Patients

The dosage in pediatric patients ≥ 6 months of age is described below in Table 2.

Table 2: Dosage in Pediatric Patients ≥ 6 months of age

Type of Infection* Dose Freq. Once every Duration? Inhalational Anthrax (post-exposure)?,§

Pediatric patients > 50 kg 500 mg 24 hr 60 days§

Pediatric patients < 50 kg and ≥ 6 months of age

8 mg/kg

(not to exceed 250 mg

per dose)

12 hr 60 days§

Table 2: Dosage in Pediatric Patients ≥ 6 months of age

Plague?

Pediatric patients > 50 kg 500 mg 24 hr 10 to 14 days

Pediatric patients < 50 kg and ≥ 6 months of age

8 mg/kg

(not to exceed 250 mg

per dose)

12 hr 10 to 14 days

Due to Bacillus anthracis [see Indications and Usage (1.13)] and Yersinia pestis [see Indications and Usage (1.14)].

? Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.

? Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized B. anthracis. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit [see Clinical Studies (14.9)]

§ The safety of LEVAQUIN? in pediatric patients for durations of therapy beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see Warnings and Precautions (5.10), Use in Specific Populations (8.4), and Clinical Studies (14.9)]. Prolonged LEVAQUIN? therapy should only be used when the benefit outweighs the risk.

? Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.

2.3 Dosage Adjustment in Adults with Renal Impairment

Administer LEVAQUIN? with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.

No adjustment is necessary for patients with a creatinine clearance ≥ 50 mL/min.

In patients with impaired renal function (creatinine clearance <50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [see Use in Specific Populations (8.6)].

Table 3 shows how to adjust dose based on creatinine clearance.

Table 3: Dosage Adjustment in Adult Patients with Renal Impairment (creatinine clearance <50 mL/min)

Dosage in Normal Renal Function Every 24 hours Creatinine Clearance

20 to 49 mL/min

Creatinine Clearance

10 to 19 mL/min

Hemodialysis or Chronic

Ambulatory Peritoneal

Dialysis (CAPD)

750 mg 750 mg every 48 hours 750 mg initial dose, then

500 mg every 48 hours 750 mg initial dose, then 500 mg every 48 hours

500 mg 500 mg initial dose, then

250 mg every 24 hours 500 mg initial dose, then

250 mg every 48 hours

500 mg initial dose, then

250 mg every 48 hours

250 mg No dosage adjustment

required 250 mg every 48 hours.

If treating uncomplicated UTI,

then no dosage adjustment is

required

No information on dosing

adjustment is available

2.4 Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal

Cations, Multivitamins

LEVAQUIN? Tablets and Oral Solution

LEVAQUIN? Tablets and Oral Solution should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution [see Drug Interactions (7.1) and Patient Counseling Information (17.2)].

LEVAQUIN? Injection

LEVAQUIN? Injection should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line [see Dosage and Administration (2.6)].

2.5 Administration Instructions

Food and LEVAQUIN? Tablets and Oral Solution

LEVAQUIN? Tablets can be administered without regard to food. It is recommended that LEVAQUIN? Oral Solution be taken 1 hour before or 2 hours after eating.

LEVAQUIN? Injection

Caution: Rapid or bolus intravenous infusion of LEVAQUIN? has been associated with hypotension and must be avoided. LEVAQUIN? Injection should be infused intravenously slowly over a period of not less than 60 or 90 minutes, depending on the dosage. LEVAQUIN? Injection should be administered only by intravenous infusion. It is not for intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.

Hydration for Patients Receiving LEVAQUIN? Tablets, Oral Solution, and Injection

Adequate hydration of patients receiving oral or intravenous LEVAQUIN? should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones [see Adverse Reactions (6.1) and Patient Counseling Information (17.2)].

2.6 Preparation of Intravenous Product

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Because only limited data are available on the compatibility of LEVAQUIN? Injection with other intravenous substances, additives or other medications should not be added to

LEVAQUIN? Injection Premix in Single-Use Flexible Containers and LEVAQUIN? Injection in Single-Use Vials, or infused simultaneously through the same intravenous line. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed before and after infusion of LEVAQUIN? Injection with an infusion solution compatible with LEVAQUIN? Injection and with any other drug(s) administered via this common line.

LEVAQUIN? Injection in Single-Use Vials

Single-use vials require dilution prior to administration.

LEVAQUIN? Injection is supplied in single-use vials containing a concentrated levofloxacin solution with the equivalent of 500 mg (20 mL vial) and 750 mg (30 mL vial) of levofloxacin in Water for Injection, USP. The 20 mL and 30 mL vials each contain 25 mg of levofloxacin/mL. These LEVAQUIN? Injection single-use vials must be further diluted with an appropriate solution prior to intravenous administration [see Table 4]. The concentration of the resulting diluted solution should be 5 mg/mL prior to administration.

Compatible Intravenous Solutions: Any of the following intravenous solutions may be used to prepare a 5 mg/mL levofloxacin solution with the approximate pH values:

Table 4: Compatible Intravenous Solutions

Intravenous Fluids Final pH of LEVAQUIN? Solution

0.9% Sodium Chloride Injection, USP 4.71

5% Dextrose Injection, USP 4.58

5% Dextrose/0.9% NaCl Injection 4.62

5% Dextrose in Lactated Ringers 4.92

Plasma-Lyte? 56/5% Dextrose Injection 5.03

4.61

5% Dextrose, 0.45% Sodium Chloride, and

0.15% Potassium Chloride Injection

Sodium Lactate Injection (M/6) 5.54

Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final intravenous solution. Since the vials are for single-use only, any unused portion remaining in the vial should be discarded. When used to prepare two 250 mg doses from the 20 mL vial containing 500 mg of levofloxacin, the full content of the vial should be withdrawn at once using a single-entry procedure, and a second dose should be prepared and stored for subsequent use [see Stability of LEVAQUIN? Injection Following Dilution].

Prepare the desired dosage of levofloxacin according to Table 5:

Table 5: Preparation of LEVAQUIN? Intravenous Solution

Volume of Diluent Infusion Time Desired Dosage Strength From Appropriate Vial,

Withdraw Volume

250 mg 10 mL (20 mL Vial) 40 mL 60 min

500 mg 20 mL (20 mL Vial) 80 mL 60 min

750 mg 30 mL (30 mL Vial) 120 mL 90 min

For example, to prepare a 500 mg dose using the 20 mL vial (25 mg/mL), withdraw 20 mL and dilute with a compatible intravenous solution to a total volume of 100 mL.

This intravenous drug product should be inspected visually for particulate matter prior to administration. Samples containing visible particles should be discarded.

Stability of LEVAQUIN? Injection Following Dilution: LEVAQUIN? Injection, when diluted in a compatible intravenous fluid to a concentration of 5 mg/mL, is stable for 72 hours when stored at or below 25°C (77°F) and for 14 days when stored under refrigeration at 5°C (41°F) in plastic intravenous containers. Solutions that are diluted in a compatible intravenous solution and frozen in glass bottles or plastic intravenous containers are stable for 6 months when stored at -20°C (-4°F). Thaw frozen solutions at room temperature 25°C (77°F) or in a refrigerator 8°C (46°F). Do not force thaw by microwave irradiation or water bath immersion. Do not refreeze after initial thawing.

LEVAQUIN? Injection Premix in Single-Use Flexible Containers (5 mg/mL)

LEVAQUIN? Injection is also supplied in flexible containers within a foil overwrap. These contain a premixed, ready to use levofloxacin solution in 5% dextrose (D5W) for single-use. The 100 mL premixed flexible containers contain either 250 mg/50 mL or 500 mg/100 mL of levofloxacin solution. The 150 mL flexible container contains 750 mg/150 mL of levofloxacin solution. The concentration of each container is 5 mg/mL. No further dilution of these preparations is necessary. Because the premix flexible containers are for single-use only, any unused portion should be discarded.

Instructions for the Use of LEVAQUIN? Injection Premix in Flexible Containers:

1. Tear outer wrap at the notch and remove solution container.

2. Check the container for minute leaks by squeezing the inner bag firmly. If leaks are

found, or if the seal is not intact, discard the solution, as the sterility may be

compromised.

3. Do not use if the solution is cloudy or a precipitate is present.

4. Use sterile equipment.

5. WARNING: Do not use flexible containers in series connections. Such use could

result in air embolism due to residual air being drawn from the primary container

before administration of the fluid from the secondary container is complete.

Preparation for Administration:

1. Close flow control clamp of administration set.

2. Remove cover from port at bottom of container.

3. Insert piercing pin of administration set into port with a twisting motion until the pin

is firmly seated. NOTE: See full directions on administration set carton.

4. Suspend container from hanger.

5. Squeeze and release drip chamber to establish proper fluid level in chamber during

infusion of LEVAQUIN? Injection Premix in Flexible Containers.

6. Open flow control clamp to expel air from set. Close clamp.

7. Regulate rate of administration with flow control clamp.

3 DOSAGE FORMS AND STRENGTHS

TABLETS, Film-coated, capsule-shaped

? 250 mg terra cotta pink tablets, imprinted with "250" on one side and "LEVAQUIN"

on the other

? 500 mg peach tablets, imprinted with "500" on one side and "LEVAQUIN" on the other

? 750 mg white tablets, imprinted with "750" on one side and "LEVAQUIN" on the other

ORAL SOLUTION, 25 mg/mL, clear yellow to clear greenish-yellow color

INJECTION, Single-Use Vials of concentrated solution for dilution for intravenous infusion, clear yellow to clear greenish-yellow in appearance

?20 mL vial of 25 mg/mL levofloxacin solution, equivalent to 500 mg of levofloxacin ?30 mL vial of 25 mg/mL levofloxacin solution, equivalent to 750 mg of levofloxacin

INJECTION (5 mg/mL in 5% Dextrose) Premix in Single-Use Flexible Containers, for intravenous infusion

?100 mL container, fill volume 50 mL (equivalent to 250 mg levofloxacin)

?100 mL container, fill volume 100 mL (equivalent to 500 mg levofloxacin)

?150 mL container, fill volume 150 mL (equivalent to 750 mg levofloxacin)

4 CONTRAINDICATIONS

LEVAQUIN? is contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials [see Warnings and Precautions (5.3)].

5 WARNINGS AND PRECAUTIONS

5.1 Tendinopathy and Tendon Rupture

Fluoroquinolones, including LEVAQUIN?, are associated with an increased risk of tendinitis and tendon rupture in all ages. This adverse reaction most frequently involves the Achilles tendon, and rupture of the Achilles tendon may require surgical repair. Tendinitis and tendon rupture in the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites have also been reported. The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is further increased in older patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Factors, in addition to age and corticosteroid use, that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. Tendinitis and tendon rupture have been reported in patients taking fluoroquinolones who do not have the above risk factors. Tendon rupture can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported. LEVAQUIN? should be discontinued if the patient experiences pain, swelling, inflammation or rupture of a tendon. Patients should be advised to rest at the first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug. [see Adverse Reactions (6.3); Patient Counseling Information (17.3)].

5.2 Exacerbation of Myasthenia Gravis

Fluoroquinolones, including LEVAQUIN?, have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis. Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use in persons with myasthenia gravis. Avoid LEVAQUIN? in patients with a known history of myasthenia gravis [see Adverse Reactions (6.3); Patient Counseling Information (17.3)].

5.3 Hypersensitivity Reactions

Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported in patients receiving therapy with fluoroquinolones, including LEVAQUIN?. These reactions often occur following the first dose. Some reactions have been accompanied by cardiovascular collapse, hypotension/shock, seizure, loss of consciousness, tingling, angioedema (including tongue, laryngeal, throat, or facial edema/swelling), airway obstruction (including bronchospasm, shortness of breath, and acute respiratory distress), dyspnea, urticaria, itching, and other serious skin reactions. LEVAQUIN? should be discontinued immediately at the first appearance of a skin rash or any other sign of hypersensitivity. Serious

acute hypersensitivity reactions may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated [see Adverse Reactions (6); Patient Counseling Information (17.3)].

5.4 Other Serious and Sometimes Fatal Reactions

Other serious and sometimes fatal events, some due to hypersensitivity, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with fluoroquinolones, including LEVAQUIN?. These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following:

? fever, rash, or severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson Syndrome);

?vasculitis; arthralgia; myalgia; serum sickness;

?allergic pneumonitis;

?interstitial nephritis; acute renal insufficiency or failure;

?hepatitis; jaundice; acute hepatic necrosis or failure;

? anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; agranulocytosis; pancytopenia; and/or other

hematologic abnormalities.

The drug should be discontinued immediately at the first appearance of skin rash, jaundice, or any other sign of hypersensitivity and supportive measures instituted [see Adverse Reactions (6); Patient Counseling Information (17.3)].

5.5 Hepatotoxicity

Post-marketing reports of severe hepatotoxicity (including acute hepatitis and fatal events) have been received for patients treated with LEVAQUIN?. No evidence of serious drug-associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days. Most cases of severe hepatotoxicity were not associated with hypersensitivity [see Warnings and Precautions (5.4)]. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. LEVAQUIN? should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see Adverse Reactions (6); Patient Counseling Information (17.3)].

5.6 Central Nervous System Effects

Convulsions, toxic psychoses, increased intracranial pressure (including pseudotumor cerebri) have been reported in patients receiving fluoroquinolones, including LEVAQUIN? . Fluoroquinolones may also cause central nervous system stimulation which may lead to tremors, restlessness, anxiety, lightheadedness, confusion, hallucinations, paranoia, depression, nightmares, insomnia, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving LEVAQUIN?, the drug should be discontinued and appropriate measures instituted. As with other fluoroquinolones, LEVAQUIN? should be used with caution in patients with a known or suspected central nervous system (CNS) disorder that may predispose them to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose them to seizures or lower the seizure threshold (e.g., certain drug therapy, renal dysfunction). [see Adverse Reactions (6); Drug Interactions (7.4, 7.5); Patient Counseling Information (17.3)].

5.7 Clostridium difficile-Associated Diarrhea

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including LEVAQUIN?, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDA

D. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated [see Adverse Reactions (6.2), Patient Counseling Information (17.3)].

5.8 Peripheral Neuropathy

Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving fluoroquinolones, including LEVAQUIN?. Symptoms may occur soon after initiation of LEVAQUIN? and may be irreversible. LEVAQUIN? should be discontinued

immediately if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness or other alterations of sensation including light touch, pain, temperature, position sense, and vibratory sensation [see Adverse Reactions (6), Patient Counseling Information (17.3)].

5.9 Prolongation of the QT Interval

Some fluoroquinolones, including LEVAQUIN?, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. Rare cases of torsade de pointes have been spontaneously reported during postmarketing surveillance in patients receiving fluoroquinolones, including LEVAQUIN?. LEVAQUIN? should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval [see Adverse Reactions (6.3), Use in Specific Populations (8.5), and Patient Counseling Information (17.3)].

5.10 Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in

Animals

LEVAQUIN? is indicated in pediatric patients (6 months of age and older) only for the prevention of inhalational anthrax (post-exposure) and for plague [see Indications and Usage (1.13, 1.14)]. An increased incidence of musculoskeletal disorders (arthralgia, arthritis, tendinopathy, and gait abnormality) compared to controls has been observed in pediatric patients receiving LEVAQUIN? [see Use in Specific Populations (8.4)].

In immature rats and dogs, the oral and intravenous administration of levofloxacin resulted in increased osteochondrosis. Histopathological examination of the weight-bearing joints of immature dogs dosed with levofloxacin revealed persistent lesions of the cartilage. Other fluoroquinolones also produce similar erosions in the weight-bearing joints and other signs of arthropathy in immature animals of various species [see Animal Toxicology and/or Pharmacology (13.2)].

5.11 Blood Glucose Disturbances

As with other fluoroquinolones, disturbances of blood glucose, including symptomatic hyper-and hypoglycemia, have been reported with LEVAQUIN?, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. If a hypoglycemic reaction occurs in a patient being treated with LEVAQUIN?, LEVAQUIN?

should be discontinued and appropriate therapy should be initiated immediately [see Adverse Reactions (6.2); Drug Interactions (7.3); Patient Counseling Information (17.4)].

5.12 Photosensitivity/Phototoxicity

Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, “V” area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of fluoroquinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if photosensitivity/phototoxicity occurs [see Adverse Reactions (6.3); Patient Counseling Information (17.3)].

5.13 Development of Drug Resistant Bacteria

Prescribing LEVAQUIN? in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria [see Patient Counseling Information (17.1)].

6 ADVERSE REACTIONS

6.1 Serious and Otherwise Important Adverse Reactions

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:

?Tendon Effects [see Warnings and Precautions (5.1)]

?Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.2)]

?Hypersensitivity Reactions [see Warnings and Precautions (5.3)]

?Other Serious and Sometimes Fatal Reactions [see Warnings and Precautions (5.4)] ?Hepatotoxicity [see Warnings and Precautions (5.5)]

?Central Nervous System Effects [see Warnings and Precautions (5.6)]

?Clostridium difficile-Associated Diarrhea [see Warnings and Precautions (5.7)]

?Peripheral Neuropathy that may be irreversible [see Warnings and Precautions (5.8)] ?Prolongation of the QT Interval [see Warnings and Precautions (5.9)]

?Musculoskeletal Disorders in Pediatric Patients [see Warnings and Precautions (5.10)] ?Blood Glucose Disturbances [see Warnings and Precautions (5.11)]

?Photosensitivity/Phototoxicity [see Warnings and Precautions (5.12)]

?Development of Drug Resistant Bacteria [see Warnings and Precautions (5.13)]

Hypotension has been associated with rapid or bolus intravenous infusion of LEVAQUIN? . LEVAQUIN? should be infused slowly over 60 to 90 minutes, depending on dosage [see Dosage and Administration (2.5)].

Crystalluria and cylindruria have been reported with quinolones, including LEVAQUIN? . Therefore, adequate hydration of patients receiving LEVAQUIN? should be maintained to prevent the formation of a highly concentrated urine [see Dosage and Administration (2.5)].

6.2 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to LEVAQUIN? in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was < 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with LEVAQUIN? for a wide variety of infectious diseases [see Indications and Usage (1)]. Patients received LEVAQUIN? doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. Treatment duration was usually 3–14 days, and the mean number of days on therapy was 10 days.

The overall incidence, type and distribution of adverse reactions was similar in patients receiving LEVAQUIN? doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of LEVAQUIN? due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily nausea (0.6%); vomiting (0.4%); dizziness (0.3%); and headache (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily nausea (0.6%), vomiting (0.5%); dizziness (0.3%); and headache (0.3%).

Adverse reactions occurring in ≥1% of LEVAQUIN?-treated patients and less common adverse reactions, occurring in 0.1 to <1% of LEVAQUIN?-treated patients, are shown in Table 6 and Table 7, respectively. The most common adverse drug reactions (≥3%) are naus ea, headache, diarrhea, insomnia, constipation, and dizziness.

Table 6: Common (≥1%) Adverse Reactions Reported in Clinical Trials with LEVAQUIN?

System/Organ Class Adverse Reaction %

(N=7537)

Infections and Infestations moniliasis 1 Psychiatric Disorders insomnia* [see Warnings and Precautions (5.6)] 4 Nervous System Disorders

headache

dizziness [see Warnings and Precautions (5.6)] 6 3

Respiratory, Thoracic and

Mediastinal Disorders

dyspnea [see Warnings and Precautions (5.3)] 1

Gastrointestinal Disorders nausea

diarrhea

constipation

abdominal pain

vomiting

dyspepsia 7 5 3 2 2 2

Skin and Subcutaneous Tissue Disorders rash [see Warnings and Precautions (5.3)]

pruritus

2

1

Reproductive System and Breast Disorders vaginitis

1?

General Disorders and Administration Site Conditions edema

injection site reaction

chest pain

1

1

1

* N=7274

? N=3758 (women)

Table 7: Less Common (0.1 to 1%) Adverse Reactions Reported in Clinical Trials with LEVAQUIN? (N=7537)

System/Organ Class Adverse Reaction

Infections and Infestations genital moniliasis

Blood and Lymphatic System Disorders anemia

thrombocytopenia granulocytopenia

[see Warnings and Precautions (5.4)]

Immune System Disorders allergic reaction [see Warnings and Precautions (5.3,5.4)] Metabolism and Nutrition Disorders hyperglycemia

hypoglycemia

[see Warnings and Precautions (5.11)]

hyperkalemia

Psychiatric Disorders anxiety

agitation

confusion

depression

hallucination

nightmare*

[see Warnings and Precautions (5.6)]

Table 7: Less Common (0.1 to 1%) Adverse Reactions Reported in Clinical Trials with LEVAQUIN? (N=7537)

System/Organ Class Adverse Reaction

sleep disorder*

anorexia

abnormal dreaming*

Nervous System Disorders tremor

convulsions

[see Warnings and Precautions (5.6)]

paresthesia [see Warnings and Precautions (5.8)]

vertigo

hypertonia

hyperkinesias

abnormal gait

somnolence*

syncope

Respiratory, Thoracic and

Mediastinal Disorders

epistaxis

Cardiac Disorders cardiac arrest

palpitation

ventricular tachycardia

ventricular arrhythmia

Vascular Disorders phlebitis

Gastrointestinal Disorders gastritis

stomatitis

pancreatitis

esophagitis

gastroenteritis

glossitis

pseudomembranous/ C. difficile colitis [see Warnings and Precautions

(5.7)]

Hepatobiliary Disorders abnormal hepatic function

increased hepatic enzymes

increased alkaline phosphatase

Skin and Subcutaneous Tissue

Disorders

urticaria [see Warnings and Precautions (5.3)]

Musculoskeletal and Connective Tissue Disorders arthralgia

tendinitis

[see Warnings and Precautions (5.1)] myalgia

skeletal pain

Renal and Urinary Disorders abnormal renal function

acute renal failure [see Warnings and Precautions (5.4)]

* N = 7274

In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment

HPLC法测定盐酸左氧氟沙星片的含量

HPLC法测定盐酸左氧氟沙星片的含量 摘要:目的:对HPLC及UV测定盐酸左氧氟沙星片的含量进行比较。方法:高效液相色谱法选择色谱柱为Agilent C18 (150 mm×4.6 mm,5 μm),流动相为醋酸铵高氯酸钠溶液(pH=2.2)-乙腈(85:15),流速为1.0mL·min-1,检测波长为294nm;紫外分光光度法选择294nm波长测定含量.结果:HPLC法中盐酸左氧氟沙星片在2.05ug·mL-1 ~51.15ug·mL-1范围内线性关系良好.回归方程Y =523247X-23331(r=0.9995),加样回收率平均值为100.36%,RSD 1.8%。结论:HPLC法及紫外分光光度法均准确性、重复性高、精密度好,可考虑将紫外分光光度法作为盐酸左氧氟沙星含量测定的替代方法使用。 关键词:高效液相法;紫外分光光度法;盐酸左氧氟沙星 左氧氟沙星是氧氟沙星的L-型光学活性异构体,因其抗菌谱广、抗菌作用强、不良反应率较低,而被广泛使用[1]。2015版药典推荐高效液相法来分析本品及其相关剂型,考虑到基层药物监测机构尚不能完全普及高效液相设备[2],本文对比分析高效液相法及紫外分光光度法测定盐酸左氧氟沙星含量。 1 材料 1.1 仪器与试药 岛津LC-20A (改为LC-2010CHT)型高效液相色谱仪;岛津UV-2501(改为UV-2450)型紫外分光光度计;超声波清洗器;乙腈由国药集团化学试剂有限公司提供(改为霍尼韦尔贸易(上海)有限公司提供),为色谱醇;磷酸、醋酸铵、高氯酸钠均为分析纯;盐酸左氧氟沙星对照品(美国西格玛公司,批号:160122)(中国食品药品检定研究院,批号:130455-20116);盐酸左氧氟沙星片(四川科伦药业股份有限公司)。 2 方法 2.1 高效液相法 2.1.1 色谱条件[2] 色谱柱选择Agilent C18 (150 mm×4.6 mm,5 μm),,流动相:醋酸铵高氯酸钠溶液(取醋酸铵4.0g和高氯酸钠7.0g,加水1300ml使溶解,用磷酸调节pH值至2.2)-乙腈(85:15),检测波长:294 nm, 进样量10μl,1.0 mL/min流速,柱温为室温(25℃)。 2.1.2 溶液的制备 2.1.2.1 供试品溶液的制备 精密称取20片盐酸左氧氟沙星,研细后混合均匀,精密称取上述供试品50mg置于50ml 容量瓶中,加入0.1mol/l盐酸溶解适量并定量稀释至刻度,经微孔滤膜(0.45um)过滤,取续滤液待用。 2.1.2.2 对照品溶液的制备 精密称取盐酸左氧氟沙星对照品10.23mg于100ml容量瓶中,用适量0.1mol/l盐酸稀释至刻度,摇匀即得。 2.1.3 方法学考察 2.1. 3.1 精密度试验 在“2.1.1”项色谱条件下,对照品溶液过0.45um滤膜后重复进样6次,每次10ul,分别测定峰面积,并计算6组数据所得的相对标准偏差RSD,结果为1.7%<2.0%,符合药典规定,提示,本组方法精密度良好。 2.1. 3.2 重复性试验 选择同批号盐酸左氧氟沙星片6份,精密称定后,根据供试品“2.1.2.1”项操作制备供试品溶液,采用“2.1.1”项色谱条件,进样10ul,采集6份样品的色谱图,计算溶液的相对标准偏差RSD = 1.3% (小于2.0%),符合标准规定,提示本组方法具有较好的重复性。 2.1. 3.3 稳定性试验

左氧氟沙星片说明书

左氧氟沙星片说明书 【篇一:盐酸左氧氟沙星片说明书】 快易捷药品网 【药品名称】 盐酸左氧氟沙星片 【英文或拉丁名】 levofloxacin hydrochloride tablets 【主要成分】 本品主要成分为盐酸左氧氟沙星 【化学名】 (s)-(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧-7h-吡啶并[1,2,3-de]-[1,4] 苯并噁嗪-6-羧酸盐酸盐一水合物 【性状】 本品为类白色或淡黄色片。 【药理毒理】 本品为氧氟沙星的左旋体,其抗菌活性约为氧氟沙星的2倍,它的 主要作用机制为抑制细菌dna旋转酶活性,抑制细菌dna复制。本 品具有抗菌谱广、抗菌作用强的特点,对多数肠杆菌科细菌,如肺 炎克雷白菌、变形杆菌属、伤寒沙门菌属、志贺菌属、部分大肠杆 菌等有较强的抗菌活性,对部分葡萄球菌、肺炎链球菌、流感杆菌、绿脓杆菌、淋球菌、衣原体等也有良好的抗菌作用。 【吸收、分布、消除】 左氧氟沙星0.3g静注(n=8)和口服(n=12)后 药代动力学参数的平均值 给药 cmax auc(0~24) t(1/2) 肾清除率 静注 6.27 20.73 6.28 145.55 口服 4.04 22.62 6.48 162.80 [auc(0~48)] 左氧氟沙星在体内组织中分布广泛。主要以原型药由尿中排出,口 服给药后48小时内,尿中原型药排出量约占给药量的87%;72小 时内粪便中的排出药量少于给药量的4%;约5%的药物以无活性代 谢物的形式由尿中排出。

肾功能减退的患者左氧氟沙星清除率下降,消除半衰期延长,为避 免药物蓄积,应进行剂量调整。血液透析和连续腹膜透析(capd)不 影响左氧氟沙星从体内排除。 【适应症】 本品适用于敏感细菌引起的下列轻、中度感染: 呼吸系统感染:急性支气管炎、慢性支气管炎急性发作、弥漫性细 支气管炎、支气管扩张合并感染、肺炎、扁桃体炎(扁桃体周围脓肿); 泌尿系统感染:肾盂肾炎、复杂性尿路感染等; 生殖系统感染:急性前列腺炎、急性副睾炎、宫腔感染、子宫附件炎、盆腔炎(疑有厌氧菌感染时可合用甲硝唑); 皮肤软组织感染:传染性脓疱病、蜂窝组织炎、淋巴管(结)炎、 皮下脓肿、肛周脓肿等; 肠道感染:细菌性痢疾、感染性肠炎、沙门菌属肠炎、伤寒及副伤寒; 败血症、粒细胞减少及免疫功能低下患者的各种感染; 其他感染:乳腺炎、外伤、烧伤及手术后伤口感染、腹腔感染(必 要时合用甲硝唑)、胆囊炎、胆管炎、骨与关节感染以及五官科感 染等。 【用法与用量】 口服,成人每次0.1~0.2g,每日两次。病情偏重者可增为每日三次。【不良反应】 用药期间可能出现恶心、呕吐、腹部不适、腹泻、食欲不振、腹痛、腹胀等症状,失眠、头晕、头痛等神经系统症状和皮疹、搔痒等。 亦可出现一过性肝功能异常,如血清转氨酶增高、血清总胆红素增 加等。上述不良反应发生率在0.1~5%之间。偶见血中尿素氮上升、倦怠、发热、心悸、味觉异常等。一般均能耐受,疗程结束后迅速 消失。 【禁忌症】 对喹诺酮类药物过敏者、妊娠及哺乳期妇女、18岁以下患者禁用。【注意事项】 1.肾功能不全者应减量或延长给药间期,重度肾功能不全者慎用。 2.有中枢神经系统疾病及癫痫史患者应慎用。

LEVOFLOXACIN左氧氟沙星 台湾,用药,说明

LEVOFLOXACIN 左氧氟沙星 <<商品名>> 台灣健保藥品- B a c f l o c i n倍樂欣膜衣錠, C r a v i t可樂必妥膜衣錠,L e f l o d a l佐淨菌膜衣錠,L e v o f l o x a c i n樂優清 膜衣錠,R o z o x i n樂作欣膜衣錠,V o r o t a l樂富妥膜衣錠. 美國-L e v a q u i n 加拿大-L e v a q u i n;N o v o-L e v o f l o x a c i n;P m s-L e v o f l o x a c i n C r a v i t(智利,香港,印尼,日本,馬來西亞,巴基斯坦, 新加坡,泰國);L e v a q u i n(阿根廷,巴西,秘魯);L e v o c i n (印尼,菲律賓,泰國); T a v a n i c (阿根廷,奧地利,比利時,瑞士,德國,芬蘭,法國,愛爾蘭,以色列,巴拿馬, 秘魯,葡萄牙,瑞典,薩爾瓦多,委內瑞拉) <<藥物作用>> L e v o f l o x a c i n為一種稱為"Q u i n o l o n e"(崑)類的抗生素。是一種強力而廣效的抗生素。此藥的藥理作用主要是能夠 破壞細菌遺傳基因D N A複製時所須的促旋酶(D N A g y r a s e)﹑使細菌蛋白質合成過程受阻並影響細菌正常地生長和繁殖,最後導致細菌的死亡。L e v o f l o x a c i n可用於多種細菌所引起的感染如慢性支氣管炎﹑細菌性結膜炎﹑細菌性前列腺炎﹑細菌性鼻竇炎﹑社區感染性肺炎﹑複 雜性尿路感染﹑角膜潰瘍﹑皮膚和/或皮下組織感染﹑吸入性炭疽熱,醫院感染性肺炎﹑急性腎盂腎炎 等。此藥對感冒,流感或其它濾過性病毒所引起的感染 則無效。 <<用法>> L e v o f l o x a c i n通常是一天服用一次﹑可空腹或與食物一起服用﹑病患應該養成每日於固定服藥的習慣﹑使藥物能

度他雄胺软胶囊fda说明书

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. AVODART (dutasteride) Soft Gelatin Capsules Initial U.S. Approval: 2001 ---------------------------RECENT MAJOR CHANGES--------------------Warnings and Precautions, Evaluation for Other Urological 03/2012 Diseases (5.3) ----------------------------INDICATIONS AND USAGE---------------------AVODART is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: (1.1) x improve symptoms, x reduce the risk of acute urinary retention, and x reduce the risk of the need for BPH-related surgery. AVODART in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. (1.2) Limitations of Use: AVODART is not approved for the prevention of prostate cancer. (1.3) -----------------------DOSAGE AND ADMINISTRATION ----------------Monotherapy: 0.5 mg once daily. (2.1) Combination with tamsulosin: 0.5 mg once daily and tamsulosin 0.4 mg once daily. (2.2) Dosing considerations: Swallow whole. May take with or without food. (2) ---------------------DOSAGE FORMS AND STRENGTHS -------------- 0.5-mg soft gelatin capsules (3) -------------------------------CONTRAINDICATIONS------------------------ x Pregnancy and women of childbearing potential. (4, 5.4, 8.1) x Pediatric patients. (4) FULL PRESCRIBING INFORMATION: CONTENTS* 1INDICATIONS AND USAGE 1.1Monotherapy 1.2Combination With Alpha Adrenergic Antagonist 1.3Limitations of Use 2DOSAGE AND ADMINISTRATION 2.1Monotherapy 2.2Combination With Alpha Adrenergic Antagonist 3DOSAGE FORMS AND STRENGTHS 4 C O NTRAINDICATI O NS 5WARNINGS AND PRECAUTIONS 5.1Effects on Prostate-Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection 5.2Increased Risk of High-Grade Prostate Cancer 5.3Evaluation for Other Urological Diseases 5.4Exposure of Women—Risk to Male Fetus 5.5B lood Donation 5.6Effect on Semen Characteristics 6ADVERSE REACTIONS 6.1Clinical Trials Experience 6.2Postmarketing Experience 7DRUG INTERACTIONS 7.1Cytochrome P450 3A Inhibitors 7.2Alpha Adrenergic Antagonists 7.3Calcium Channel Antagonists 7.4Cholestyramine 7.5Digoxin 7.6Warfarin x Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to AVODART or other 5 alpha-reductase inhibitors. (4) -----------------------WARNINGS AND PRECAUTIONS ---------------- x AVODART reduces serum prostate-specific antigen (PSA) concentration by approximately 50%. However, any confirmed increase in PSA while on AVODART may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.1) x AVODART may increase the risk of high-grade prostate cancer. (5.2, 6.1) x Prior to initiating treatment with AVODART, consideration should be given to other urological conditions that may cause similar symptoms. (5.3) x Women who are pregnant or could become pregnant should not handle AVODART Capsules due to potential risk to a male fetus. (5.4, 8.1) x Patients should not donate blood until 6 months after their last dose of AVODART. (5.5) ------------------------------ADVERSE REACTIONS ----------------------- The most common adverse reactions, reported in t1% of subjects treated with AVODART and more commonly than in subjects treated with placebo, are impotence, decreased libido, ejaculation disorders, and breast disorders. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or https://www.360docs.net/doc/9213394164.html,/medwatch. -------------------------------DRUG INTERACTIONS------------------------ Use with caution in patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir). (7) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 10/2012 8USE IN SPECIFIC POPULATIONS 8.1Pregnancy 8.3Nursing Mothers 8.4Pediatric Use 8.5Geriatric Use 8.6Renal Impairment 8.7Hepatic Impairment 10OVERDOSAGE 11DESCRIPTION 12CLINICAL PHARMACOLOGY 12.1Mechanism of Action 12.2Pharmacodynamics 12.3Pharmacokinetics 13NONCLINICAL TOXICOLOGY 13.1Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2Animal Toxicology and/or Pharmacology 14CLINICAL STUDIES 14.1Monotherapy 14.2Combination With Alpha-Blocker Therapy (CombAT) 16HOW SUPPLIED/STORAGE AND HANDLING 17PATIENT COUNSELING INFORMATION 17.1PSA Monitoring 17.2Increased Risk of High-Grade Prostate Cancer 17.3Exposure of Women—Risk to Male Fetus 17.4Blood Donation *Sections or subsections omitted from the full prescribing information are not listed.

2盐酸左氧氟沙星胶囊工艺规程2020

一、目的与范围: 规定盐酸左氧氟沙星胶囊生产过程的各项技术要求,为其它涉及该过程的标准操作规程、原始记录等技术文件制订提供依据。 二、产品概述: 2.1产品名称: 2.1.1通用名:盐酸左氧氟沙星胶囊 2.1.2英文名:Levofloxacin Hydrochloride Capsules 2.1.3汉语拼音:Yansuan Zuoyangfushaxing Jiaonang 2.2剂型:胶囊剂 2.3性状:本品为硬胶囊。 2.4规格:0.1g/粒(以左氧氟沙星计)。 2.5包装:6粒/板×1板/盒×400盒/箱;8粒\板×1板\盒×400盒\箱;10粒\板×1板\盒×600盒\箱;10粒\板×2板\盒×500盒\箱;12粒\板×1板\盒×500盒\箱; 2.6批量:60万粒/批次;100万粒/批次;注:每批生产投料量应严格根据规定的批量投料。 2.7功能主治:本品为氧氟沙星的基旋体,抗菌活性是氧氟沙星的2倍。它的主要作用机理是通过抑制细菌DNA旋转酶的活性,阻碍细菌DNA的复制而达到抗菌作用。具有抗菌谱广,抗菌作用强的特点,对大多数肠杆菌科细菌以及多数革兰阴性细菌及部分革兰阳性细菌有较强的搞菌活性。 2.8用法用量: 成人每日200mg—300mg,分别2-3次口服。病情较重者每日剂量可增至600mg分3次口服。另外,可根据的种类及症状适当增减。 2.9 批准文号:国药准字H20066862。 2.10 贮藏:本品应遮光,密封保存; 2.11有效期:24个月。 三、处方和依据: 3.1 处方 盐酸左氧氟沙星 115.1g 干淀粉 40g

二氧化硅适量 制成 1000粒 注:本制剂用混合粉末直接充填,不需制粒。 3.2处方依据:《中华人民共和国药典》2020年版二部。 3.3生产工艺流程图: 质量控制1 检查是否按处方配料、细度、干淀粉水份。 质量控制2 混合时间、混合量、是否符合工艺。 质量控制3 胶囊装量差异、外观是否符合要求。 质量控制4 批号打印是否正确,热封是否严密,裁切是否符合要求,有无缺粒。 质量控制5 检查说明书、小盒、大箱是否与药物一致;有无缺粒,批号、文字、数量是否准确。 质量控制6 检查是否有成品合格证。 五、生产过程及工艺条件: 5.1生产准备: 5.1.1 文件准备 5.1.1.1批制剂指令明确了生产品种名称、规格、生产批号、生产批量、投料量等; 5.1.1.2生产品种应有执行标准、工艺规程、岗位标准操作程序。 5.1.1.3生产地点应有环境要求的文件规定和环境清洁标准操作程序。 5.1.1.4使用设备应有相应的设备操作、维护保养、清洁标准操作程序。 5.1.1.5容器具清洁应有相应的标准操作程序。 5.1.1.6应有岗位所需生产记录(含清场),房间使用卡、设备状态标识卡、生产物料领料单等空白表格。 5.1.1.7其他有关执行文件。 5.1.1.8上述文件均应为现行文件。

左氧氟沙星滴眼液说明书

左氧氟沙星滴眼液说明书 【药品名称】 通用名称:左氧氟沙星滴眼液 商品名称:左氧氟沙星滴眼液(可乐必妥) 拼音全码:ZuoYangFuShaXingDiYanYe(KeLeBiTuo) 【主要成份】盐酸左氧氟沙星。化学名:(S)-(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧-7H-吡啶骈 【性状】本品为淡黄绿色的澄明溶液。 【适应症/功能主治】多种病原菌引起的外眼部感染性疾病。 【规格型号】24.4mg:5ml 【用法用量】一般1天3次,每次滴眼1滴。根据症状可适当增减。推荐疗程:细菌性结膜炎7天、细菌性角膜炎10-14天。或遵医嘱。【不良反应】最常报道的不良反应是暂时性视力下降、发烧、头痛、暂时性眼热、眼痛或不适、咽炎及畏光,发生率约1%-3%。其他发生率低于1%的不良反应有:过敏、眼睑水肿、眼睛干燥及瘙痒。【禁忌】对盐酸左氧氟沙星或其他喹诺酮类药物及可乐必妥任何组分过敏者禁用。 【注意事项】1.可乐必妥只限于滴眼用,不能用于结膜下注射,也不能直接滴入眼睛前房内。 2.和其他抗感染药一样,延长使用可乐必妥将可能导致非敏感微生物的过度生长,包括真菌。因此可乐必妥不应长期使用。 3.喹诺酮类药物全身用药时,即使只有一次,也有

可能发生过敏反应,某些反应伴有心血管虚脱、丧失知觉、血管性水肿(包括咽、喉或脸部水肿)、气道阻塞、呼吸困难、荨麻疹、瘙痒等。如果发生皮疹或其他过敏反应的症状,应立即停止用药并咨询医生。 4.使用时注意避免污染容器前端。 5.建议细菌性结膜炎、角膜炎患者不戴接触透镜。请仔细阅读说明书并遵医嘱使用。 【儿童用药】1岁以下婴儿使用可乐必妥的疗效及安全性尚未确立。未成熟动物口服喹诺酮类药物可引起关节病,但没有证据证明左氧氟沙星滴眼液对承重关节有任何影响。 【老年患者用药】老年人使用可乐必妥的疗效及安全性与其他成人患者无总体差别。 【孕妇及哺乳期妇女用药】由于目前尚缺乏怀孕妇女使用左氧氟沙星滴眼液的资料,因此对于怀孕妇女,只有在判断药物的潜在利益大于对胎儿的潜在风险时,才能使用可乐必妥。根据氧氟沙星的研究报道,推测左氧氟沙星可通过人乳汁排泄,因此哺乳期妇女慎用。 【药物相互作用】尚缺乏有关可乐必妥的药物相互作用资料。但是,已经证明某些喹诺酮类药物全身用药时可增加茶碱的血药浓度,干扰咖啡因的代谢,增加口服抗凝药华法林及其衍生物的作用,如果同服环孢菌素,患者可能会有一过性血清肌酐升高。 【药物过量】尚不明确。 【药理毒理】左氧氟沙星为氧氟沙星的左旋体,其抗菌活性约为氧氟沙星的两倍,它的主要作用机理是通过抑制细菌拓朴异构酶Ⅳ及DNA旋转酶(均为Ⅱ型拓朴异构酶)的活性,阻碍细菌DNA的复制而

盐酸左氧氟沙星片说明书

盐酸左氧氟沙星片说明书 【药品名称】 通用名称:盐酸左氧氟沙星片 商品名称:盐酸左氧氟沙星片(彼迪) 英文名称:Levofloxacin Hydrochloride Tablets 拼音全码:YanSuanZuoYangFuShaXingPian(BiDi) 【主要成份】本品主要成份为盐酸左氧氟沙星。 【成份】 化学名:(S)-(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪)-7-氧-7H-吡啶骈[1,2,3-de]-[1,4]苯并噁嗪-6-羧酸盐酸盐的水合物分子量:C18H20FN3O4·HCl·H2O 【性状】本品薄膜衣片,除去薄膜衣后显白色。 【适应症/功能主治】适用于敏感菌引起的:1.泌尿生殖系统感染,包括单纯性、复杂性尿路感染、细菌性前列腺炎、淋病奈瑟菌尿道炎或宫颈炎(包括产酶株所致者)。2.呼吸道感染,包括敏感革兰阴性杆菌所致支气管感染急性发作及肺部感染。3.胃肠道感染,由志贺菌属、沙门菌属、产肠毒素大肠杆菌、亲水气单胞菌、副溶血弧菌等所致。4.伤寒。5.骨和关节感染。6.皮肤软组织感染。7.败血症等全身感染。 【规格型号】 0.2g*12s

【用法用量】盐酸左氧氟沙星口服制剂和注射剂用于上述感染性疾病(详见适应症)的治疗,通用的用法用量如下所示,但必须结合疾病严重程度由临床医生最终决定。1.剂量和给药方法(1)肾功能正常患者中剂量盐酸左氧氟沙星口服制剂的常用剂量为250mg或750mg,每24小时口服一次,根据感染情况按照下表所示服用。【详情请见说明书】 【不良反应】 1.胃肠道反应:腹部不适或疼痛、腹泻、恶心或呕吐。 2.中枢神经系统反应可有头昏、头痛、嗜睡或失眠。 3.过敏反应:皮疹、皮肤瘙痒,偶可发生渗出性多形性红斑及血管神经性水肿。光敏反应较少见。 4.偶可发生:①癫痫发作、精神异常、烦躁不安、意识模糊、幻觉、震颤。②血尿、发热、皮疹等间质性肾炎表现。③静脉炎。④结晶尿,多见于高剂量应用时。⑤关节疼痛。 5.少数患者可发生血清氨基转移酶升高、血尿素氮增高及周围血象白细胞降低,多属轻度,并呈一过性。 【禁忌】对本品及氟喹诺酮类药过敏的患者禁用。 【注意事项】 1.由于目前大肠埃希菌对氟喹诺酮类药物耐药者多见,应在给药前留取尿培养标本,参考细菌药敏结果调整用药。2.本品大剂量应用或尿pH值在7以上时可发生结晶尿。为避免结晶尿的发生,宜多饮水,保持24小时排尿量在1200ml以上。3.肾功能减退者,需根据肾功能调整给药剂量。4.应用本品时应避免过度暴露于阳光,如发生光敏反应或其他过敏症状需停药。5.肝功能减退时,如属重度(肝硬化腹水)可减少药物清除,血药浓度增高,肝、肾功

盐酸左氧氟沙星注射液说明书--左克

盐酸左氧氟沙星注射液说明书 【药品名称】 通用名:盐酸左氧氟沙星注射液 英文名:Levofloxacin Hydrochloride and Sodium Chloride Injection 汉语拼音:Yansuan Zuoyangfushaxing Lühuana Zhusheye 商品名:左克 【成份】 本品主要成份为盐酸左氧氟沙星;其化学名称为(S)-(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-羧酸盐酸盐-水合物。 化学结构式: 分子式:C18H20FN3O4·HCl·H2O 分子量:415.85 Cas No:177325-13-2 辅料为:注射用水 【性状】本品为淡黄绿色或黄绿色澄明液体。 【适应症】 本品适用于敏感细菌所引起的下列重度感染: 呼吸系统感染:急性支气管炎、慢性支气管炎急性发作、弥漫性细支气管炎、支气管扩张合并感染、肺炎、扁桃体炎(扁桃体周脓肿); 泌尿系统感染:肾盂肾炎、复杂性尿路感染等; 生殖系统感染:急性前列腺炎、急性副睾炎、宫腔感染、子宫附件炎、盆腔炎(疑有厌氧菌感染时可合用甲硝唑); 皮肤软组织感染:传染性脓疱病、蜂窝组织炎、淋巴管(结)炎、皮下脓肿、肛周脓肿等; 肠道感染:细菌性痢疾、感染性肠炎、沙门菌属肠炎、伤寒及副伤寒; 败血症、粒细胞减少及免疫功能低下患者的各种感染; 其他感染:乳腺炎、外伤、烧伤及手术后伤口感染、腹腔感染(必要时合用甲硝唑)、胆囊炎、胆管炎、骨与关节感染以及五官科感染等。 【规格】 2ml:盐酸左氧氟沙星0.1g(以左氧氟沙星计算) 【用法用量】 静脉滴注:成人一日400ml(0.4g),分2次静滴。重度感染患者及病原菌对本品敏感性较差者(如铜绿假单胞菌),每日最大剂量可增至600ml(0.6g),分2次静滴。 【不良反应】 用药期间可能出现恶心、呕吐、腹部不适、腹泻、食欲不振、腹痛、腹胀消化症状;失眠、头晕、头痛等神经系统症状;皮疹、瘙痒、红斑及注射部位发红、发痒或静脉炎等症状。亦

盐酸左氧氟沙星眼用凝胶说明书

盐酸左氧氟沙星眼用凝胶说明书 【药品名称】 通用名称:盐酸左氧氟沙星眼用凝胶 商品名称:盐酸左氧氟沙星眼用凝胶(杰奇) 英文名称:Levofloxacin Hydrochloride Eye Gel 拼音全码:YanSuanZuoYangFuShaXingYanYongNingJiao(JieQi) 【主要成份】本品主要成份为盐酸左氧氟沙星,其化学名称为:(S)-(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪)-7-氧-7H-吡啶骈[1,2,3-de]-[1,4]苯骈噁嗪-6-羧酸盐酸盐的水合物。 【成份】 分子量:C18H20FN3O4·HCl·H2O 【性状】本品为淡黄色或淡黄绿色透明的凝胶。 【适应症/功能主治】本品适用于细菌性结膜炎、角膜炎、角膜溃疡、泪囊炎、术后感染等外眼感染。 【规格型号】5g 【用法用量】涂于眼下睑穹窿部,每日3次(早、中、晚各一次)。【不良反应】偶有一过性的刺激症状。 【禁忌】对本品成份氧氟沙星或喹诺酮类药物过敏者禁用。 【注意事项】1.不宜长期使用。 2.使用中出现过敏症状,应立即停止使用。 3.只限于眼用。请仔细阅读说明书并遵医嘱使用。 【儿童用药】未进行该项实验且无可靠参考文献。

【老年患者用药】未进行该项实验且无可靠参考文献。 【孕妇及哺乳期妇女用药】未进行该项实验且无可靠参考文献。【药物相互作用】如与其他药物同时使用可能会发生药物相互作用,详情请咨询医师或药师。 【药物过量】未进行该项实验且无可靠参考文献。 【药理毒理】药理作用:本品属喹诺酮类抗菌药,为氧氟沙星的左旋体,其抗菌活性约为氧氟沙星的2倍,主要作用机制为抑制细菌DNA旋转酶的活性,抑制细菌DNA的复制。本品具有抗菌谱广、抗菌作用强的特点,对多数肠杆菌科细菌如肺炎克雷白菌、变形杆菌属、伤寒杆菌属、志贺菌属、部分大肠杆菌等有较强的抗菌活性,对部分葡萄球菌、肺炎链球苗、流感杆菌、绿脓杆菌、淋球菌、衣原体等也有良好的抗菌作用。毒理研究:未进行该项实验且无可靠参考文献。【药代动力学】未进行该项实验且无可靠参考文献。 【贮藏】遮光,凉暗处保存。 【包装】药用聚乙烯/铝/聚乙烯复合软膏管,5g/支,1支/盒。【有效期】24 月 【执行标准】WS-587(X-499)-2001 【批准文号】国药准字H20040234

左氧氟沙星针说明书

左氧氟沙星针说明书 左氧氟沙星针说明书 篇一: 左氧氟沙星氯化钠注射液说明书--可乐必妥左氧氟沙星氯化钠注射液说明书【药品名称】通用名: 左氧氟沙星氯化钠注射液商品名: 可乐必妥英文名: Levflxacin and Sdium Chlride Injectin 汉语拼音: Zuyangfushaxing Lvhuana Zhusheye 【成份】本品主要成份为左氧氟沙星,其他成份为氯化钠、盐酸、氢氧化钠(PH调节剂,必要时添加)和注射用水。化学名称: (S)-(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并 [1,2,3-de]-[1,4]-苯并口恶嗪-6-羧酸半水合物 化学结构式: 分子式:C18H20FN34·1/2H2 分子量:370.38 Cas N: 100986-85-4, 【性状】本品为淡黄色的澄明液体。【适应症】本品适用于敏感细菌所引起的下列中、重度感染: 1.呼吸系统感染: 急性支气管炎、慢性支气管炎急性发作、弥漫性细支气管炎、支气管扩张合并感染、肺炎、扁桃体炎(扁桃体周脓肿); 2.泌尿系统感染: 肾盂肾炎、复杂性尿路感染等; 3.生殖系统感染: 急性前列腺炎、急性副睾炎、宫腔感染、子宫附件炎、盆腔炎(疑有厌氧菌感染时可合用甲硝唑); 4.皮肤软组织感染: 传染性脓疱病、蜂窝组织炎、淋巴管(结)炎、皮下脓肿、肛周脓肿等; 5.肠道感染:

细菌性痢疾、感染性肠炎、沙门菌属肠炎、伤寒及副伤寒; 6.败血症、粒细胞减少及免疫功能低下患者的各种感染; 7.其它感染:乳腺炎、外伤、烧伤及手术后伤口感染、腹腔感染(必要时合用甲硝唑)、胆囊炎、胆管炎、骨与关节感染以及五官科感染等。【规格】100ml:左氧氟沙星0.5g与氯化钠0.9g。【用法与用量】静脉滴注:100ml:0.5g,成人一次0.5g(1瓶),一日1次。(塑料瓶的使用方法见说明书背面)【不良反应】用药期间可能出现恶心、呕吐、腹部不适、腹泻、食欲缺乏、腹痛、腹胀等症状;失眠、头晕、头痛等神经系统症状;皮疹、搔痒、红斑及注射部位发红、发痒或静脉炎等症状。亦可出现一过性肝功能异常,如血氨基转移酶增高、血清总胆红素增加等。上述不良反应发生率在0.1%~5%之间。偶见血中尿素氮上升、倦怠、发热、心悸、味觉异常及注射后血管痛等,一般均能耐受,疗程结束后迅速消失。【禁忌症】对喹诺酮类药物过敏者、妊娠及哺乳期妇女、18岁以下患者禁用。【注意事项】 1.本制剂专供静脉滴注,滴注时间为每100ml至少60分钟。本制剂不宜与其他药物同瓶混合静脉滴注,或在同一根静脉输液管内进行静脉滴注。 2.肾功能减退者应减量或慎用。肌酐清除率: 50ml/分正常剂量 20~50ml/分首剂0.5g,以后每24小时0.25g 10~19ml/分首剂0.5g,以后每24小时0.125g 10ml/分首剂0.5g,以后每24小时0.125g 3.有中枢神经系统疾病及癫痫史患者应慎用。 4.喹诺酮类药物尚可引起少见的光毒性反应(发生率 0.1%)。在接受本品治疗时应避免过度阳光曝晒和人工紫外线。如出现光敏反应或皮肤损伤时应停用本品。此外偶有用药后发生跟踺炎或跟踺断裂的报告,故如有上述症状发生时须立即停药并休息,严禁运动,直至症状消失。偶有剧烈连续或血样的腹泻,可能是伪膜性肠炎的症状,一旦发生请立即停药并咨询医生。【孕妇及哺乳期妇女用药】 1.因不能确保妊娠妇女的用药安全,所以妊娠或有可能妊娠的妇女禁用。 2.因药物经乳汁排泄,所以哺乳期妇女禁用。如必须使用本品,

FDA 行业指南 中英对照 待完成

Guidance for Industry Container Closure Systems for Packaging Human Drugs and Biologics Chemistry, Manufacturing and Controls Documentation 行业指南 人用药品及生物制品的包装容器和封装系统:化学,生产和控制文件 指南发布者:美国FDA下属的CDER及CBER 发布日期:May 1999 TABLE OF CONTENTS目录 I. INTRODUCTION介绍 II. BACKGROUND 背景 A. Definitions 定义 B. CGMP, CPSC and USP Requirements on Containers and Closures. CGMP, CPSC和 USP对容器和密封的要求 C. Additional Considerations 其他需要考虑的事项 III. QUALIFICATION AND QUALITY CONTROL OF PACKAGING COMPONENTS包装组件的合格要求以及质量控制 A. Introduction 介绍 B. General Considerations 通常要求 C. Information That Should Be Submitted in Support of an Original Application for Any Drug Product 为支持任何药品的原始申请所必须提供的信息 D. Inhalation Drug Products 吸入性药品 E. Drug Products for Injection and Ophthalmic Drug Products 注射剂和眼科用药 F. Liquid-Based Oral and Topical Drug Products and Topical Delivery Systems 液体口服 和外用药品和外用给药系统 G. Solid Oral Dosage Forms and Powders for Reconstitution 口服固体剂型和待重新溶解 的粉末 H. Other Dosage Forms 其他剂型 IV. POSTAPPROVAL PACKAGING CHANGES 批准后的包装变更 V. TYPE III DRUG MASTER FILES 药品主文件第III类 A. General Comments 总体评述 B. Information in a Type III DMF 第III类DMF中包括的信息 VI. BULK CONTAINERS 大包装容器 A. Containers for Bulk Drug Substances 用于原料药的容器 B. Containers for Bulk Drug Products 用于散装药品的容器 ATTACHMENT A 附件A REGULATORY REQUIREMENTS 药政要求

左氧氟沙星针说明书(共5篇)

篇一:左氧氟沙星氯化钠注射液说明书--可乐必妥 左氧氟沙星氯化钠注射液说明书 【药品名称】 通用名:左氧氟沙星氯化钠注射液 商品名:可乐必妥 英文名:levofloxacin and sodium chloride injection 汉语拼音:zuoyangfushaxing lvhuana zhusheye 【成份】 本品主要成份为左氧氟沙星,其他成份为氯化钠、盐酸、氢氧化钠(ph调节剂,必要时添加)和注射用水。 化学名称: (s)-(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7h-吡啶并 [1,2,3-de]-[1,4]-苯并口恶嗪-6-羧酸半水合物 化学结构式: 分子式:c18h20fn3o4·1/2h2o 分子量:370.38 cas no:100986-85-4, 【性状】本品为淡黄色的澄明液体。 【适应症】 本品适用于敏感细菌所引起的下列中、重度感染: 1.呼吸系统感染:急性支气管炎、慢性支气管炎急性发作、弥漫性细支气管炎、支气管扩张合并感染、肺炎、扁桃体炎(扁桃体周脓肿); 2.泌尿系统感染:肾盂肾炎、复杂性尿路感染等; 3.生殖系统感染:急性前列腺炎、急性副睾炎、宫腔感染、子宫附件炎、盆腔炎(疑有厌氧菌感染时可合用甲硝唑); 4.皮肤软组织感染:传染性脓疱病、蜂窝组织炎、淋巴管(结)炎、皮下脓肿、肛周脓肿等; 5.肠道感染:细菌性痢疾、感染性肠炎、沙门菌属肠炎、伤寒及副伤寒; 6.败血症、粒细胞减少及免疫功能低下患者的各种感染; 7.其它感染:乳腺炎、外伤、烧伤及手术后伤口感染、腹腔感染(必要时合用甲硝唑)、胆囊炎、胆管炎、骨与关节感染以及五官科感染等。 【规格】100ml:左氧氟沙星0.5g与氯化钠0.9g。 【用法与用量】 静脉滴注:100ml:0.5g,成人一次0.5g(1瓶),一日1次。 (塑料瓶的使用方法见说明书背面) 【不良反应】 用药期间可能出现恶心、呕吐、腹部不适、腹泻、食欲缺乏、腹痛、腹胀等症状;失眠、头晕、头痛等神经系统症状;皮疹、搔痒、红斑及注射部位发红、发痒或静脉炎等症状。亦可出现一过性肝功能异常,如血氨基转移酶增高、血清总胆红素增加等。上述不良反应发生率 在0.1%~5%之间。偶见血中尿素氮上升、倦怠、发热、心悸、味觉异常及注射后血管痛等,一般均能耐受,疗程结束后迅速消失。 【禁忌症】

设计方案(左氧氟沙星)

盐酸左氧氟沙星片 人体相对生物利用度及生物等效性试验 临床研究方案 华中科技大学同济医学院临床药理研究所 华中科技大学同济医学院国家药品临床研究基地 2004年3月

前言 左氧氟沙星(Levofloxacin)又称可乐必妥、利复星、左氧沙星、Cravit、CVFX,由日本Daiichi(第一制药株式会社)公司开发研制;1993年1月在日本首次上市。国内首次注册时间是1995年,注册号为:X950251。 【药理作用】左氧氟沙星是消旋氧氟沙星的左旋体,其抗菌活性是氧氟沙星的2倍。本品作用于细菌的DNA旋转酶(拓扑异构酶II),通过抑制DNA旋转酶的活性来阻碍DNA复制,从而杀灭细菌;它还可以溶解细菌的部分结构。本品对包括厌氧菌在内的革兰氏阳性菌和阴性菌具有广谱抗菌作用,对葡萄球菌、肺炎球菌、淋球菌、化脓性链球菌、溶血性链球菌、肠球菌、大肠杆菌、克雷白氏杆菌、绿脓杆菌、变形杆菌等显示有较强的抗菌活性。另外,本品对衣原体、支原体也有抗菌作用。 【体内过程】左氧氟沙星口服吸收迅速、完全,生物利用度接近100%,同服食物不影响吸收。口服后能迅速有效地渗透到全身,在组织或体液中地药物浓度高于血浆浓度。健康成人单剂量口服本品50、100、200mg后,血浆药物浓度达峰时间为0.9~2.4h,峰浓度分别为0.6、1.2、2.0μg/ml,表观分布容积为1.09~1.26L/kg。本品在体内几乎不代谢,血浆半衰期为4.3~6.0h,在口服24h内,用药剂量的80%~85%以原形从尿液中排泄。 【用法用量】(1)口服:每次0.1~0.2g,每日2~3次,疗程为3~7天。用于淋病治疗时,可单剂量顿服0.4~0.6g。(2)静脉滴注:每次0.2~0.3g,每日2次。 【不良反应】本品的不良反应与氧氟沙星相同,但比较轻。主要

相关文档
最新文档